test

Available Trials

Colorectal Cancer

10
A Phase II Multi-center, Randomized, Placebo-Controlled Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer
Disease/Condition: Colon
Principal Investigator: Howard Hochster
A Phase III, Double Blind, Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Disease/Condition: Colon
Principal Investigator: Sajid Khan
A Randomized Phase II Study of Exercise and Metformin in Colorectal and Breast Cancer Survivors
Principal Investigator: Melinda Irwin
Novartis Signature - LGX818 for pts with BRAFV600 mutated tumors
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Skin | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach
Principal Investigator: Joseph Paul Eder
Phase 2 study of PF-05212384 plus irinotecan vs. cetuximab plus irinotecan in KRAS & NRAS wt mCLC
Disease/Condition: Anus | Colon
Principal Investigator: Howard Hochster
Phase 3 Study of Adjuvant Regorafenib vs. Placebo for Patients with Stage 4 colorectal cancer
Disease/Condition: Colon | Liver | Rectum
Principal Investigator: Howard Hochster
Phase Ib Trial of MPDL3280A with Bevacizumab or with Bevacizumab + FOLFOX in Patients with Solid Tumors
Disease/Condition: Colon | Lung | Rectum
Principal Investigator: Howard Hochster
Phase Ib/II study of LGX818 and cetuximab or LGX818, BYL719 and cetuximab in BRAF mutant mCRC
Disease/Condition: Colon | Rectum
Principal Investigator: Howard Hochster
Pilot Trial of KD018 with Neo-Adj Concurrent Chemo-RT in PTs with Rectal CA
Disease/Condition: Rectum
Principal Investigator: Susan Higgins
STEAM (Sequencing Triplet with Avastin and Maintenance): Folfoxiri/Bevacizumab Regiments (Concurrent and Sequential) vs. Folfox/Bevacizumab in First-Line Metastatic Colorectal Cancer
Disease/Condition: Colon
Principal Investigator: Howard Hochster

Gastric and Esophageal

10
A Phase I/II, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Disease/Condition: Bladder | Breast - Female | Lung | Pancreas | Stomach
Principal Investigator: Joseph Paul Eder
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects with Advanced Solid Tumors
Disease/Condition: Bladder | Breast - Female | Lip, Oral Cavity and Pharynx | Stomach
Principal Investigator: Lajos Pusztai
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients with Refractory Gastrointestinal Stromal Tumor
Disease/Condition: Cancer | Other Digestive Organ
Principal Investigator: Howard Hochster
A RANDOMIZED, MULTICENTER, ADAPTIVE PHASE II/III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE (T-DM1) VERSUS TAXANE (DOCETAXEL OR PACLITAXEL) IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE GASTRIC CANCER, INCLUDING ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION
Disease/Condition: Adenocarcinoma of the Gastroesophageal Junction | Esophagus | Gastric Cancer | Stomach
Principal Investigator: Howard Hochster
Novartis Signature - LGX818 for pts with BRAFV600 mutated tumors
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Skin | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach
Principal Investigator: Joseph Paul Eder
Phase 2 Single Arm, Two Cohort Study Evaluating AMG 337 in Subjects with MET Amplif. GI/GEJ/E cancer
Disease/Condition: Esophagus | Stomach
Principal Investigator: Howard Hochster
Phase 2 Study of Cabazitaxel in Refractory Metastatic Gastric and Gastroesophageal Adenocarcinoma
Disease/Condition: Esophagus | Other Digestive Organ
Principal Investigator: Jeremy Kortmansky
Phase Ib Trial of MPDL3280A with Bevacizumab or with Bevacizumab + FOLFOX in Patients with Solid Tumors
Disease/Condition: Colon | Lung | Rectum
Principal Investigator: Howard Hochster
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Disease/Condition: Esophagus
Principal Investigator: Daniel Boffa

Liver Cancer

Pancreatic Cancer

10
A Phase I/II, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Disease/Condition: Bladder | Breast - Female | Lung | Pancreas | Stomach
Principal Investigator: Joseph Paul Eder
A Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Disease/Condition: Pancreas
Principal Investigator: Stacey Stein
Novartis Signature - LGX818 for pts with BRAFV600 mutated tumors
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Skin | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach
Principal Investigator: Joseph Paul Eder
Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer
Disease/Condition: Pancreas
Principal Investigator: Jill Lacy